Skip to main content
JUBILANT PHARMOVA LIMITED logo

JUBILANT PHARMOVA LIMITED — Investor Relations & Filings

Ticker · JUBLPHARMA ISIN · INE700A01033 LEI · 335800C6LDKWF4HQH833 BSE.NS Manufacturing
Open in API
Filings indexed 1,045 across all filing types
Latest filing 2022-10-29 Regulatory Filings
Country IN India
Listing BSE.NS JUBLPHARMA

About JUBILANT PHARMOVA LIMITED

https://www.jubilantpharmova.com/

Jubilant Pharmova Limited is an integrated global pharmaceutical company operating through three primary segments: Pharmaceuticals, Contract Research and Development Services (CRDS), and Proprietary Novel Drugs. The Pharmaceuticals segment specializes in radiopharmaceuticals for nuclear medicine, allergy immunotherapy, and the development and manufacturing of generic formulations. It also provides Contract Development and Manufacturing Organization (CDMO) services for sterile injectables and non-sterile products. The CRDS division offers comprehensive drug discovery and development solutions to biopharmaceutical companies worldwide. Furthermore, the Proprietary Novel Drugs segment focuses on creating innovative therapies for oncology and autoimmune diseases. The company leverages its advanced manufacturing infrastructure and research capabilities to serve global markets with a focus on complex chemistry and specialized healthcare solutions.

Recent filings

Filing Released Lang Actions
General updates
Regulatory Filings Classification · 95% confidence The document is a press release dated October 29, 2022, from Jubilant Pharmova Limited, announcing that the US FDA has classified the inspection of its Roorkee facility as "official action indicated" following an audit. The document is addressed to stock exchanges and references Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, which pertains to disclosure of material events. The content is a regulatory announcement about a compliance issue and does not contain financial statements, detailed financial analysis, or management discussion. It is not an annual or interim report, earnings release, or any detailed financial or governance report. The document is a regulatory announcement informing the market about a significant regulatory development affecting the company. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2022-10-29 English
Recording of Analysts/Institutional Investor Meet/Con. Call
Regulatory Filings Classification · 95% confidence The document is a short disclosure letter addressed to stock exchanges regarding the audio recording of an investors conference call for the quarter and half-year ended September 30, 2022. It references the conference call but does not contain the transcript or detailed financial data itself. The document length is only 1306 characters, indicating it is an announcement rather than the full call transcript. Therefore, it should be classified as a Call Transcript announcement, but since it only informs about the availability of the audio recording and does not contain the transcript text, it fits best under Regulatory Filings (RNS) as a general regulatory announcement about the call recording.
2022-10-22 English
Newspaper Advertisements
Regulatory Filings Classification · 95% confidence The document is a letter addressed to stock exchanges (BSE and NSE) regarding the submission of copies of published unaudited standalone and consolidated financial results for the quarter and half-year ended September 30, 2022. It mentions the results were published in newspapers on October 22, 2022. The document is about submitting copies of financial results, not the full financial report itself. The length is 15,000 characters, but the content is primarily an announcement of the published financial results, not the detailed report or financial statements. Therefore, this fits best as a Regulatory Filing (RNS) since it is a formal announcement to the exchanges about the publication of financial results rather than the full report or earnings release itself.
2022-10-22 English
Outcome of Board Meeting
Interim / Quarterly Report Classification · 95% confidence The document is a formal communication to stock exchanges regarding the approval of unaudited financial results for the quarter and half year ended September 30, 2022. It references Regulation 33 and 30 of the SEBI Listing Obligations and Disclosure Requirements Regulations, which govern quarterly financial disclosures. The document includes the unaudited standalone and consolidated financial results, a limited review report by auditors, and related press release and presentation. The presence of detailed financial data such as revenue, expenses, profit, and earnings per share for the quarter and half year confirms this is a comprehensive interim financial report. The document is not merely an announcement of a report but contains substantive financial data and analysis for a period shorter than a full fiscal year. Therefore, it fits the definition of an Interim / Quarterly Report (IR).
2022-10-21 English
Loss of share certificate
Regulatory Filings Classification · 95% confidence The document is a formal notification addressed to stock exchanges regarding the loss of a share certificate by a shareholder and the proposed issuance of a duplicate certificate. It references Regulation 39(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which pertains to share certificate loss and related disclosures. The content is an announcement about a specific shareholding event rather than a financial report, management change, or voting result. It does not contain financial data, earnings information, or meeting materials. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2022-10-19 English
Newspaper Advertisements
Regulatory Filings Classification · 95% confidence The document is a letter addressed to stock exchanges (BSE Limited and National Stock Exchange of India Limited) regarding the submission of newspaper advertisements for a Postal Ballot. It references a previous letter dated October 15, 2022, and encloses copies of advertisements published on October 16, 2022, related to the dispatch of notices for the Postal Ballot. The content is primarily about the communication and advertisement of the Postal Ballot process, not the Postal Ballot results or the detailed voting outcomes. There is no detailed voting result data or shareholder vote outcomes presented here, only the submission of advertisements for record and information. This fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA) only if it contained actual voting results, but since it only contains advertisements related to the Postal Ballot dispatch, it is more aligned with Regulatory Filings (RNS) as a general regulatory announcement. The document length is 12,312 characters, which is substantial, but the content is administrative and informational about the Postal Ballot advertisement, not a full report or detailed voting results. Therefore, the best classification is Regulatory Filings (RNS).
2022-10-17 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.